NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

VNRX

VolitionRX Ltd

Jun 30 • 04:00PM ET

0.7600

Dollar change -0.0777
Percentage change -9.28	%

Healthcare • Medical Devices • USA • AMEX

Peers: TMO BIO CRL ILMN EXAS QGEN DGX GH NEO MYGN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.27	Insider Own	26.10%	Shs Outstand	100.75M	Perf Week	-11.64%
Market Cap	78.30M	Forward P/E	-	EPS next Y	-0.06	Insider Trans	1.76%	Shs Float	76.14M	Perf Month	55.71%
Enterprise Value	81.82M	PEG	-	EPS next Q	-0.05	Inst Own	20.39%	Short Float	0.24%	Perf Quarter	38.18%
Income	-24.02M	P/S	59.77	EPS this Y	50.00%	Inst Trans	30.21%	Short Ratio	0.62	Perf Half Y	17.28%
Sales	1.31M	P/B	-	EPS next Y	59.14%	ROA	-171.88%	Short Interest	0.18M	Perf YTD	26.67%
Book/sh	-0.28	P/C	30.11	EPS next 5Y	-	ROE	-	52W High	0.94 -19.15%	Perf Year	24.59%
Cash/sh	0.03	P/FCF	-	EPS past 3/5Y	15.10% 5.38%	ROIC	-	52W Low	0.40 92.36%	Perf 3Y	-63.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	139.28% 135.32%	Gross Margin	1.50%	Volatility	14.34% 13.82%	Perf 5Y	-81.55%
Dividend TTM	-	EV/Sales	62.45	EPS Y/Y TTM	41.65%	Oper. Margin	-1846.75%	ATR (14)	0.09	Perf 10Y	-81.33%
Dividend Ex-Date	-	Quick Ratio	0.40	Sales Y/Y TTM	64.15%	Profit Margin	-1836.21%	RSI (14)	57.34	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	0.40	EPS Q/Q	44.96%	SMA20	12.63%	Beta	1.22	Target Price	2.90
Payout	-	Debt/Eq	-	Sales Q/Q	43.64%	SMA50	35.20%	Rel Volume	0.36	Prev Close	0.84
Employees	85	LT Debt/Eq	-	Earnings	May 16 BMO	SMA200	24.82%	Avg Volume	293.82K	Price	0.76
IPO	Apr 25, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	-38.89% -72.74%	Trades		Volume	105,464	Change	-9.28%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-25	Initiated	H.C. Wainwright	Buy	$2.50
Feb-01-23	Downgrade	The Benchmark Company	Buy → Hold
Feb-17-22	Resumed	Cantor Fitzgerald	Overweight	$8 → $7
Mar-10-21	Initiated	Cantor Fitzgerald	Overweight	$8
May-16-18	Initiated	Maxim Group	Buy	$6
May-14-18	Reiterated	The Benchmark Company	Buy	$7 → $5
Sep-07-16	Reiterated	Rodman & Renshaw	Buy	$12 → $10
Feb-01-16	Initiated	Rodman & Renshaw	Buy	$12

Jun-12-25 08:30AM	Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure (PR Newswire) +5.97%
Jun-04-25 09:00PM	Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties (PR Newswire) +5.85%
May-19-25 08:30AM	VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats (PR Newswire)
May-17-25 03:02AM	VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones (GuruFocus.com)
May-15-25 06:12PM	VolitionRX: Q1 Earnings Snapshot (Associated Press Finance) -5.22%
05:37PM	Loading…
05:37PM	VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update (PR Newswire)
09:22AM	VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-12-25 08:30AM	VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update (PR Newswire)
May-07-25 08:30AM	VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q NETs test adoption (PR Newswire)
Apr-29-25 08:30AM	VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets (PR Newswire) +9.27%
Apr-01-25 03:03AM	VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances (GuruFocus.com) -9.03%
12:31AM	VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript (Seeking Alpha)
Mar-31-25 04:05PM	VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update (PR Newswire)
Mar-28-25 08:00AM	Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025 (PR Newswire)
Mar-27-25 08:30AM	Volition to Host Virtual Investor Event on Nu.Q Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025 (PR Newswire)
08:00AM	Loading…
Mar-26-25 08:00AM	VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering (PR Newswire) -6.87%
Mar-25-25 09:30AM	VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update (PR Newswire)
Mar-21-25 08:30AM	Volition's Nu.Q Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry (PR Newswire)
Mar-20-25 08:30AM	Volition Introduces Nu.Q Cancer Blood Test in New Industry Primer for Lung Cancer (PR Newswire)
Mar-17-25 08:30AM	Volition Proudly Sponsors the 44th ISICEM Congress (PR Newswire)
Mar-13-25 08:30AM	Volition Signs first ever Nu.Q Vet Cancer Test Automation Agreement with Fujifilm Vet Systems (PR Newswire)
Mar-11-25 08:30AM	Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q Lung Cancer Test (PR Newswire)
Mar-04-25 08:30AM	Volition's Nu.Q Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time (PR Newswire)
Feb-28-25 08:30AM	Volition Showcases Nu.Q Vet Cancer Test at the 97th WVC Annual Conference (PR Newswire)
Feb-06-25 08:30AM	Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis (PR Newswire) +6.08%
Feb-05-25 09:15AM	Volition to Host Virtual Investor Event on Nu.Q NETs, "Casting a New Light on Sepsis Management", on February 14, 2025 (PR Newswire)
Jan-30-25 08:30AM	Large clinical study establishes Nu.Q NETs H3.1 as an independent predictor of 28-day mortality in sepsis (PR Newswire)
Jan-08-25 08:30AM	Volition Issues Business Review 2024 (PR Newswire)
Dec-12-24 08:00AM	VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants (PR Newswire) -6.30%
Dec-10-24 08:00AM	Study shows Nu.Q Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening (PR Newswire)
09:00AM	Loading…
Dec-06-24 09:00AM	VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering (PR Newswire) +9.93%
Nov-16-24 02:02AM	VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Nov-15-24 05:32AM	VolitionRX: Q3 Earnings Snapshot (Associated Press Finance) -5.56%
Nov-14-24 04:10PM	VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update (PR Newswire) -5.76%
07:19AM	VolitionRX Ltd (VNRX) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Nov-08-24 08:00AM	VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update (PR Newswire) +5.44%
Nov-06-24 04:10PM	Volition Appoints Timothy I. Still as Chairman (PR Newswire) +9.29%
Oct-31-24 08:00AM	Multiple studies show Nu.Q NETs test could predict sepsis patients at risk of deteriorating (PR Newswire) -9.39%
Oct-09-24 08:00AM	Volition to share new 'NETs in sepsis management' data insights at upcoming webinar (PR Newswire) -9.42%
Oct-03-24 08:00AM	Volition hosts NETs in sepsis management symposium at ESICM Lives 2024 (PR Newswire) +9.32%
Sep-30-24 04:10PM	Volition Appoints Dr. Ethel Rubin as an Independent Director (PR Newswire) +5.82%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
Sep-11-24 08:00AM	Volition Hosts KOL Roundtable on Sepsis (PR Newswire) +7.21%
Aug-14-24 05:31PM	VolitionRX: Q2 Earnings Snapshot (Associated Press Finance)
04:10PM	VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update (PR Newswire)
Aug-09-24 08:00AM	VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering (PR Newswire) -7.19%
Aug-06-24 08:00AM	VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update (PR Newswire)
Jul-09-24 08:30AM	Volition appoints PharmaVentures for Capture PCR and oncology portfolio licensing (PR Newswire)
Jun-27-24 08:00AM	VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting (PR Newswire)
Jun-14-24 09:00AM	Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
May-29-24 08:00AM	VolitionRx Limited to Present at Jefferies Global Healthcare Conference (PR Newswire) +10.74%
May-15-24 03:01AM	VolitionRX Ltd (VNRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances and ... (GuruFocus.com)
May-13-24 05:11PM	VolitionRX: Q1 Earnings Snapshot (Associated Press Finance) +5.85% -14.53%
04:10PM	VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update (PR Newswire)
May-08-24 08:00AM	VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update (PR Newswire)
Apr-23-24 08:00AM	Nu.Q Vet Cancer Test launched in-clinic in U.S. and Europe through Antech (PR Newswire) +41.67%
Mar-27-24 12:31PM	VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-25-24 04:10PM	VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update (PR Newswire)
Mar-21-24 08:30AM	VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update (PR Newswire) -8.75%
Mar-20-24 08:30AM	Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan (PR Newswire) -5.88%
Mar-19-24 04:30PM	Volition appoints Dr Andrew Retter as Chief Medical Officer (PR Newswire)
Feb-02-24 08:00AM	Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar (PR Newswire)
Jan-18-24 04:54AM	Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances (InvestorPlace)
Jan-04-24 08:00AM	Volition Issues Business Review 2023 (PR Newswire) -18.10%
Dec-05-23 10:25AM	Sidoti Events, LLC's Virtual December Small-Cap Conference (ACCESSWIRE)
08:00AM	VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre (PR Newswire)
Nov-16-23 09:15AM	VolitionRx Limited (AMEX:VNRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-15-23 05:08AM	VolitionRX: Q3 Earnings Snapshot (Associated Press Finance)
Nov-14-23 04:10PM	VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update (PR Newswire) -7.29%
Nov-08-23 08:00AM	VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business Update (PR Newswire) +6.00%
Nov-06-23 06:24AM	Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland (PR Newswire)
Nov-02-23 08:19AM	VNRX: Breakthrough Cancer Detection Method Disclosed at ESMO and in a Webinar - preliminary proof of concept work indicates simple blood test should be able to detect several types of cancer, potentially at Stages I & II (Zacks) +12.03%
Oct-23-23 08:00AM	Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer (PR Newswire) +7.00%
Oct-19-23 08:00AM	Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic Shock (PR Newswire) -24.17%
Oct-18-23 12:00PM	US Ambassador Adler visits Belgian Volition (PR Newswire) +5.69%
Oct-16-23 08:00AM	Volition Presents Three Cancer Detection Abstracts at ESMO 2023 (PR Newswire)
Oct-13-23 08:00AM	Volition Publishes Key Opinion Leader Roundtable Report on NETs in Sepsis (PR Newswire) +6.45%
Oct-02-23 08:00AM	Volition to Reveal New Cancer Detection Method Insights at Upcoming Webinar (PR Newswire) +8.85%
Sep-13-23 08:00AM	Volition Hosts Key Opinion Leader Roundtable on Sepsis Management (PR Newswire)
Aug-25-23 04:30AM	VolitionRx (VNRX): Review of 2Q 2023; Distribution Footprint of Nu.Q Vet Cancer Test is expanding. Prolific Schedule of Clinical Papers & Posters. (Zacks)
Aug-14-23 05:27PM	VolitionRX: Q2 Earnings Snapshot (Associated Press Finance)
04:10PM	VolitionRx Limited Announces Second Quarter 2023 Financial Results and Business Update (PR Newswire)
Aug-09-23 08:00AM	VolitionRx Limited Schedules Second Quarter 2023 Earnings Conference Call and Business Update (PR Newswire)
Jun-23-23 04:10PM	VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriters (PR Newswire)
06:00AM	VNRX: Highlights of Capital Markets Day (Nu.Q NETs & Nu.Q Vet); Heska being acquired by Mars (increases Nu.Q Vet distribution footprint); 13 MM share offering completed (Zacks Small Cap Research)
Jun-05-23 04:10PM	VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock (PR Newswire)
Jun-01-23 09:15AM	VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common Stock (PR Newswire)
May-31-23 04:01PM	VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock (PR Newswire) +8.41%
May-11-23 12:45PM	VolitionRX: Q1 Earnings Snapshot (AP Finance)
07:00AM	Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring (PR Newswire)
May-10-23 04:10PM	VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update (PR Newswire)
May-05-23 08:00AM	VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business Update (PR Newswire)
Apr-26-23 07:30AM	VolitionRx Limited to Host Capital Markets Day at the NYSE on Thursday May 11. (PR Newswire)
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -6.78%
Mar-15-23 04:10PM	VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update (PR Newswire) -15.38% +11.69%
Mar-10-23 08:35AM	Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
08:00AM	VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update (PR Newswire)
Mar-07-23 08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for March 9th (GlobeNewswire)
Mar-06-23 04:30PM	VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com March 9th (GlobeNewswire)

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Reynolds Cameron John	President and CEO	Jun 12 '25	Buy	0.59	12,500	7,372	2,331,722	Jun 16 08:27 AM
Innes Guy Archibald	Director	Jun 03 '25	Buy	0.54	20,000	10,772	888,689	Jun 04 07:55 AM
Micallef Jacob Vincent	Chief Scientific Officer	May 19 '25	Buy	0.43	50,000	21,500	426,033	May 19 01:23 PM
Reynolds Cameron John	President and CEO	May 19 '25	Buy	0.44	20,000	8,730	2,319,222	May 19 12:43 PM
Reynolds Cameron John	President and CEO	Mar 26 '25	Buy	0.55	181,818	100,000	2,299,222	Mar 27 08:13 AM
Innes Guy Archibald	Director	Mar 26 '25	Buy	0.55	181,818	100,000	868,689	Mar 27 08:13 AM
Innes Guy Archibald	Director	Dec 09 '24	Buy	0.57	174,764	100,000	617,085	Dec 10 04:01 PM
STILL TIMOTHY I	Director	Dec 09 '24	Buy	0.57	87,382	50,000	1,487,382	Dec 10 04:01 PM
Micallef Jacob Vincent	Chief Scientific Officer	Dec 09 '24	Buy	0.57	43,691	25,000	394,352	Dec 10 04:01 PM
Reynolds Cameron John	President and CEO	Dec 09 '24	Buy	0.57	139,811	80,000	2,117,404	Dec 10 04:01 PM
Innes Guy Archibald	Director	Aug 20 '24	Buy	0.67	150,000	100,500	406,683	Aug 21 08:26 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VNRX

VolitionRX Ltd

Upgrade your FINVIZ experience